AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01563952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
Study NCT01563952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
Study NCT01563952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
Study NCT04060433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Therapy
Description: Swedish version of the evidence based manualized Family Therapy
Study NCT01300000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk
Description: ad lib
Study NCT01300000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational infant formula
Description: ad lib
Study NCT01300000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk based standard infant formula
Description: ad lib
Study NCT00287755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
Study NCT03662789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Isomaltoside 1000
Description: Intravenous infusion
Study NCT03662789 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0,9%
Description: Intravenous infusion
Study NCT02249351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine
Study NCT02249351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01679704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Food products
Study NCT02587104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EpiFix
Description: Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
Study NCT00005629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP gene hepatocellular carcinoma vaccine
Description: Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug
Study NCT00608803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-201-T and doxorubicin
Description: ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
Study NCT01994109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYOBLOC
Description: MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use.
Study NCT01994109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study NCT04691349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
Study NCT04564690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)
Description: Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
Study NCT04564690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular hen eggs
Description: Consumption of three regular hen eggs per day for three weeks
Study NCT02014506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT02014506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 4 and continuing until blood counts recover
Study NCT02014506 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)
Study NCT02014506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCRαβ-depleted hematopoietic cell transplantation
Study NCT02014506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Immunogenetic depletion of TCRαβ cells
Study NCT00711594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2 40mg/day
Description: Phase I step: Increased dose cohorts from low dose to MTD
Study NCT00711594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2 50mg/day
Description: Phase I step: Increased dose cohorts from low dose to MTD
Study NCT00711594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2 20mg/day
Description: Phase I step: Increased dose cohorts from low dose to MTD
Study NCT00711594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 QD
Description: Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
Study NCT01708148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group would receive a oral lactose placebo
Study NCT03816852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hucMSCs
Description: Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
Study NCT02554565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor biopsy
Description: Tumor biopsy before treatment
Study NCT02554565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample before, during and after treatment
Study NCT03083080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
Study NCT03083080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30 mL 0.5% ropivacaine is used to achieve VATS block
Study NCT03083080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
Study NCT03795038 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lipoprotein Apheresis MONET and DALI
Description: Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
Study NCT03795038 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lipoprotein Apheresis DIAMED and DALI
Description: Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
Study NCT04437459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat shake
Description: Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.
Study NCT04437459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pure glucose solution
Description: Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
Study NCT04495036 — intervention group
Intervention type: OTHER
Intervention: data collection (21-items-patient descriptive survey)
Description: Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~* Demographic data of telemedicine users and non-users~* Subjective disease perception of the dermatology patients~* Use of internet, telemedicine and telemedicine insurance model~* Patients´ willingness for additional features of telemedicine~* Advantages and disadvantages telemedicine and face-to-face consultation~* Suitable fields of dermatology for telemedicine from the patient's perspective~* Recommended structure of telemedical services by users and non-users
Study NCT04495036 — intervention group
Intervention type: OTHER
Intervention: data collection (23-items-physician descriptive survey)
Description: To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~* Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~* Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective
Study NCT02455037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Strengthening
Description: Targeted neck strengthening exercises
Study NCT01404923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti spasmodic agents
Description: best standard of care prescriptions
Study NCT01404923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alverine citrate, simeticone
Description: on-demand therapy
Study NCT04460482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared spectroscopy (NIRS)
Description: NIRS-guided PCI
Study NCT04460482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Angiography guided PCI
Study NCT00911027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound guided biopsy
Description: One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part
Study NCT00911027 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound guided systematic biopsy
Description: Current practice of ultrasound guided systematic biopsy
Study NCT01833819 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine and lidocaine
Study NCT01833819 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Study NCT02777073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza
Description: Single dose of Liraglutide
Study NCT02777073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of generic placebo
Study NCT02777073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: single dose of 10 mg dapagliflozin
Study NCT00764322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
Study NCT00764322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
Study NCT00764322 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Genetic analysis of blood sample.
Study NCT00764322 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: gene expression analysis
Description: Genetic analysis of blood sample.
Study NCT00764322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Genetic analysis of blood sample.
Study NCT02733939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home monitoring kit
Description: The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~* leaves the home without notice, since this might occur in a moment of disorientation;~* leaves a water tap open;~* forgets something on the stove;~* gets out of bed during the night and doesn't come back within a certain time interval;~* never goes to the bathroom in 24 hours;~* never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~* automatically turn on a light to help avoid a fall during the night;~* alert the caregiver when the temperature in the house falls or rises excessively;~* act as burglar alarm in some areas of the home.
Study NCT04748120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative management
Description: Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
Study NCT00764322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomic studies
Description: Genetic analysis of blood sample.
Study NCT00764322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
Study NCT00764322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
Study NCT00764322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
Study NCT00764322 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
Study NCT03741140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motivation tests
Description: Motivation tests will characterize elementary deficits of motivation
Study NCT04583267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration
Description: Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
Study NCT04317898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus plane block by ultra-sound
Description: To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
Study NCT04317898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block by ultra-sound
Description: TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
Study NCT02611934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild Therapeutic Hypothermia (MHT)
Description: The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
Study NCT04748120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative management
Description: Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~* piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~* amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~* ertapenem 1g IV every 24 hours for 3 days~* ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis.
Study NCT03919799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: ROCK-2 Inhibitor
Study NCT03919799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study NCT00886899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recanalization of a coronary chronic total occlusion
Description: Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
Study NCT02820272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NPWT with cold water
Description: Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
Study NCT00852098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap Nissen fundoplication with division of short gastric vessels
Description: Dividing short gastric vessels
Study NCT02820272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NPWT with normal saline room temp
Description: Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
Study NCT02820272 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NPWT without other intervention
Description: Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
Study NCT03642405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram examination
Description: 12-lead ECG monitored by Holter
Study NCT00852098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without division of short gastric vessels
Description: non-dividing short gastric vessels
Study NCT01876472 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessment of music perception skills
Description: A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
Study NCT02682576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial artery ultrasound imaging
Study NCT00979472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: oral
Study NCT03100006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg of IV Nivolumab is administered over 30 mins every 2 weeks
Study NCT03100006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
Study NCT03642405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography in accordance to Danish Society of Cardiology